The CPDR BRL will perform analytical validation of biomarkers and biomarker assays developed by other EDRN investigators and by other investigators. This includes Mass Spectrometry-based Detection of Multiple Candidate Biomarkers from Target Cells Enriched by Laser Capture Microdissection;Validation of Prostate Cancer Biomarkers Using the CPDR ERG Monoclonal Antibody (CPDR ERG-MAb) as a Paradigm;and Development and Testing of New Monoclonal Antibodies for Prostate Cancer Diagnosis and Prognosis Focusing on ETS family of oncoproteins and new prostate cancer markers.

Agency
National Institute of Health (NIH)
Type
NIH Inter-Agency Agreements (Y01)
Project #
ACN12011001-1-0-1
Application #
8916454
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2014
Total Cost
Indirect Cost
Name
National Cancer Institute
Department
Type
DUNS #
City
State
Country
Zip Code